Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | ATM |
Variant | D2708N |
Impact List | missense |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | ATM D2708N does not lie within any known functional domains of the Atm protein (UniProt.org). D2708N results in decreased protein expression and reduced phosphorylation of Atm and downstream targets in response to irradiation in culture (PMID: 19431188), and therefore, is predicted to lead to a loss of Atm protein function. |
Associated Drug Resistance | |
Category Variants Paths |
ATM mutant ATM inact mut ATM D2708N |
Transcript | NM_000051.4 |
gDNA | chr11:g.108335080G>A |
cDNA | c.8122G>A |
Protein | p.D2708N |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001351834.1 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
XM_017017789.2 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
NM_000051.4 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
XM_011542843 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
XM_006718843 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
XM_006718843.5 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
XM_011542843.3 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
XM_011542840 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
XM_005271562 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
NM_001351834.2 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
XM_006718843.4 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
XM_011542840.4 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
XM_005271562.6 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
XM_011542840.3 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
XM_017017790 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
XM_017017789 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
NM_000051.3 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
XM_005271562.5 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
XM_017017790.3 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
XM_047426976.1 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
XM_005271561 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
XM_047426975.1 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
XM_017017790.2 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
XM_011542843.2 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
NM_000051 | chr11:g.108335080G>A | c.8122G>A | p.D2708N | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ATM D2708N | prostate cancer | sensitive | Olaparib | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (PROfound) that supported FDA approval, Lynparza (olaparib) improved progression-free survival (7.4 vs 3.6 mo, HR 0.34, p<0.001), objective response rate (33% vs 2%, OR 20.86, p<0.001), and median overall survival (18.5 vs 15.1 mo, HR 0.64, p=0.02) over control in metastatic prostate cancer patients harboring inactivating BRCA/ATM mutations as detected by approved assays, including ATM D2708N, HR was 1.04 in ATM-mutant group (PMID: 32343890; NCT02987543). | detail... 32343890 detail... |